

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1-57. (Cancelled).

58. (Currently Amended) An assay device for identifying a leukemia of T-cell, B-cell, or myeloid lineage in a subject, said device comprising (a) a solid support; and (b) an array of immunoglobulin molecules, or derivatives thereof, immobilized to discrete regions on the solid support, wherein the array comprises from 7 to 1000 discrete regions, wherein each discrete region comprises an immunoglobulin, or derivative thereof, specific for a ~~different-cell surface~~ marker antigen, wherein the array comprises immunoglobulin molecules, specific for at least seven cell surface marker antigens, ~~wherein the at least seven cell surface marker antigens are selected from the list in Table 4, and wherein the pattern of expression of the at least seven~~ 7 to 1000 cell surface marker antigens on a leukocyte distinguishes leukemias of T-cell, B-cell, or myeloid lineage.

59-68. (Cancelled).

69. (Previously Presented) The assay device of claim 58 wherein the subject is a human.

70. (Cancelled).

71. (Previously Presented) The assay device of claim 58, wherein the immunoglobulins, or derivatives thereof, of the array are bound covalently to the solid support or wherein the immunoglobulins, or derivatives thereof, of the array are bound to a recombinant, truncated protein G that is first coated on the solid support.

72. (Previously Presented) The method of claim 58 wherein the subject is a non-human animal.

73. (Previously Presented) The method of Claim 58, wherein the immunoglobulin molecules are monoclonal antibodies.

74. (Previously Presented) The method of Claim 58, wherein the immunoglobulin molecules are polyclonal antibodies.